The adoption of redistributed manufacturing (RDM) in the healthcare sector is driven by a number of factors. These include the risk of committed capital, the impact on the complexity of existing supply chains, capacity management, sustainability requirements, and the adoption of new technologies.
The RiHN has commissioned several feasibility studies to advance the understanding of the challenges and opportunities of RDM. The below videos give an overview of each project.
The way we currently manufacture our goods is becoming increasingly unsustainable. The centralised, off-shore approach has come under threat by global economic volatility, security risks, and climate change. The rise of new technologies, such as Big Data, 3D Printing and Advanced Robotics offers opportunities to advance an alternative production method: Redistributed Manufacturing (RDM). The social, environment and economic benefits are substantial and it may even have the potential to help place the UK at the forefront of healthcare manufacturing. Watch the video to learn more.
University of Sussex
The use of Redistributed Manufacturing is ideal for the Pharma Industry, a sector that is particularly affected by long product development lead times and complex supply chains. Additive Manufacturing allows for higher or even personalised dosages, due to its precision. It lets you combine a number of pills into one, making life much easier for patients who would otherwise have to take a variety of pills on a daily basis.
Visit the web pages of the Pharma Supply Chains Centre at the University of Sussex for more details.
University of Nottingham
What are the possible modes of operating a commercial-scale distributed business for bioprinting implants containing living cells? To what extent could the existing non-routine arrangements be used for commercialisation of personalised Advanced Therapy Medicinal Products (ATMPs)? What are the needs in relation to the development of a more appropriate framework for regulation of customised products? Watch the video to learn more.
There are currently 3.2 Million people diagnosed with diabetes in the UK. 10% of the yearly budget of the NHS goes to treating this autoimmune disorder. The project seeks to improve the patient outcomes of type 1 diabetes treatment, whilst making it more efficient and reducing overall costs. The aim is to develop functional islet micro-tissue(s) by 3-D printing viable islet cells and to assess the potential this would have in terms of re-defining the supply chain for regenerative approaches to the treatment of diabetes.
Regenerative medicine has been identified by the Government as a priority technology for UK competitiveness and a healthy nation. Cell and Tissue-based therapeutics (CATBTs) are a key category of these and pose significant challenges to traditional modes of manufacturing scale-up for commercialisation. This study aims to examine a range of alternative models of re-distributed manufacturing for both autologous and allogeneic CATBTs and identify those that offer the highest probability of success for future business. Watch the video to find out more from the people behind this project or visit the Loughborough Centre for Biological Engineering site for more details.
The costs for worldwide shipping of medical devices are significant, particularly the delivery of small volumes. The investment in tooling for mass-market devices is also substantial, and beyond the means of many start-ups and SMEs. By redistributing the manufacturing of parts of a device, there is the potential to decrease its final cost, reduce the time required for the device to be available to the patient, improve the patient experience, and offer a possibility of customisation. The research will look at how a redistributed system could be achieved by using low-cost 3D printing technologies.